Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pheochromocytoma 3Paraganglioma 3Neuroendocrine Tumors 2Meningioma 2von Hippel-Lindau Disease 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Metastatic Neuroendocrine Prostate Cancer 1Kidney Neoplasms 1Hypertension 1Head and Neck Neoplasms 1Ganglioneuroma 1Ganglioneuroblastoma 1Carcinoma, Neuroendocrine 1Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 54enzalutamide 47apalutamide 37Specimen Handling 37Androgen Antagonists 34Abiraterone Acetate 32Prednisone 29darolutamide 28Radiosurgery 27Pluvicto 23Docetaxel 23abiraterone 22Radiotherapy 21Leuprolide 19Biopsy 16relugolix 14acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 14Surveys and Questionnaires 13gallium 68 PSMA-11 12Triptorelin Pamoate 12Gonadotropin-Releasing Hormone 12Radiation 11Nivolumab 112-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 11cabazitaxel 10bicalutamide 10X-Rays 10Standard of Care 10Goserelin 9Carboplatin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × gallium Ga 68 dotatate × 90 days × Clear all
NCT05691465 2026-05-27

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

National Cancer Institute (NCI)

Phase 2 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡